Compile Data Set for Download or QSAR
maximum 50k data
Found 130 with Last Name = 'kinoyama' and Initial = 'i'
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148155(US8962612, 26)
Affinity DataKi:  0.680nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148163(US8962612, 66)
Affinity DataKi:  0.75nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148169(US8962612, 80)
Affinity DataKi:  0.850nM ΔG°:  -53.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148165(US8962612, 74)
Affinity DataKi:  0.880nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148171(US8962612, 86)
Affinity DataKi:  0.950nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148154(US8962612, 23)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148156(US8962612, 28)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135790(US8853242, 162)
Affinity DataKi:  1.20nM ΔG°:  -50.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135780(US8853242, 60)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148167(US8962612, 78)
Affinity DataKi:  1.30nM ΔG°:  -52.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135785(US8853242, 152)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135783(US8853242, 148)
Affinity DataKi:  1.40nM ΔG°:  -50.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148164(US8962612, 69)
Affinity DataKi:  1.60nM ΔG°:  -52.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135782(US8853242, 147)
Affinity DataKi:  1.60nM ΔG°:  -50.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135795(US8853242, 192)
Affinity DataKi:  1.80nM ΔG°:  -49.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135792(US8853242, 170)
Affinity DataKi:  1.90nM ΔG°:  -49.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148162(US8962612, 62)
Affinity DataKi:  1.90nM ΔG°:  -51.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135796(US8853242, 211)
Affinity DataKi:  2.30nM ΔG°:  -49.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148161(US8962612, 61)
Affinity DataKi:  2.5nM ΔG°:  -51.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148157(US8962612, 44)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148166(US8962612, 76)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135788(US8853242, 160)
Affinity DataKi:  3.30nM ΔG°:  -48.4kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135789(US8853242, 161)
Affinity DataKi:  3.40nM ΔG°:  -48.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148153(US8962612, 8)
Affinity DataKi:  3.60nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148168(US8962612, 79)
Affinity DataKi:  3.70nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135781(US8853242, 114)
Affinity DataKi:  3.70nM ΔG°:  -48.1kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148160(US8962612, 60)
Affinity DataKi:  3.90nM ΔG°:  -49.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135784(US8853242, 151)
Affinity DataKi:  4.10nM ΔG°:  -47.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148170(US8962612, 81)
Affinity DataKi:  4.20nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148152(US8962612, 4)
Affinity DataKi:  4.30nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135794(US8853242, 187)
Affinity DataKi:  4.60nM ΔG°:  -47.6kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAndrogen receptor(Homo sapiens (Human))
Astellas Pharma

LigandPNGBDBM18656((2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-...)
Affinity DataKi:  4.60nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135791(US8853242, 164)
Affinity DataKi:  4.70nM ΔG°:  -47.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135786(US8853242, 157)
Affinity DataKi:  5.30nM ΔG°:  -47.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAndrogen receptor(Rattus norvegicus (Rat))
Astellas Pharma

LigandPNGBDBM18656((2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-...)
Affinity DataKi:  6.20nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135793(US8853242, 171)
Affinity DataKi:  6.20nM ΔG°:  -46.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148159(US8962612, 49)
Affinity DataKi:  6.60nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148158(US8962612, 46)
Affinity DataKi:  6.90nM ΔG°:  -48.5kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135787(US8853242, 159)
Affinity DataKi:  7.10nM ΔG°:  -46.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135779(US8853242, 6)
Affinity DataKi:  13nM ΔG°:  -45.0kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAndrogen receptor(Rattus norvegicus (Rat))
Astellas Pharma

LigandPNGBDBM18525(Bicalutamide | CHEMBL409 | N-[4-cyano-3-(trifluoro...)
Affinity DataKi:  14nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
TargetAndrogen receptor(Homo sapiens (Human))
Astellas Pharma

LigandPNGBDBM18525(Bicalutamide | CHEMBL409 | N-[4-cyano-3-(trifluoro...)
Affinity DataKi:  19nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
TargetCarboxylic ester hydrolase(Equus caballus (Horse))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359284(CHEMBL1928379)
Affinity DataKi:  1.60E+3nMAssay Description:Inhibition of equine serum BChE using butyrylthiocholine iodide as a substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAcetylcholinesterase(Electrophorus electricus (Electric eel))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359293(CHEMBL1928397)
Affinity DataKi:  3.20E+3nMAssay Description:Inhibition of Electrophorus electricus Type V-S acetylcholinesterase using acetylcholine iodide as substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProgesterone receptor(Rattus norvegicus)
Astellas Pharma

LigandPNGBDBM18656((2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-...)
Affinity DataKi:  3.30E+3nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAcetylcholinesterase(Electrophorus electricus (Electric eel))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359287(CHEMBL1928382)
Affinity DataKi:  3.90E+3nMAssay Description:Inhibition of Electrophorus electricus Type V-S acetylcholinesterase using acetylcholine iodide as substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAcetylcholinesterase(Electrophorus electricus (Electric eel))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359285(CHEMBL1928380)
Affinity DataKi:  5.70E+3nMAssay Description:Inhibition of Electrophorus electricus Type V-S acetylcholinesterase using acetylcholine iodide as substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAcetylcholinesterase(Electrophorus electricus (Electric eel))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359289(CHEMBL1928384)
Affinity DataKi:  6.80E+3nMAssay Description:Inhibition of Electrophorus electricus Type V-S acetylcholinesterase using acetylcholine iodide as substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProgesterone receptor(Rattus norvegicus)
Astellas Pharma

LigandPNGBDBM18525(Bicalutamide | CHEMBL409 | N-[4-cyano-3-(trifluoro...)
Affinity DataKi:  7.20E+3nMAssay Description:The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd] where [L] is the concentration of labeled ligand a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAcetylcholinesterase(Electrophorus electricus (Electric eel))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50359284(CHEMBL1928379)
Affinity DataKi:  1.09E+4nMAssay Description:Inhibition of Electrophorus electricus Type V-S acetylcholinesterase using acetylcholine iodide as substrate by spectrophotometric Ellman's assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: